Journal of Cataract & Refractive Surgery
Volume 34, Issue 9 , Pages 1509-1512 , September 2008

Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: Aqueous drug absorption and prostaglandin E2 levels

  • Frank A. Bucci Jr., MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Frank A. Bucci Jr, MD, Bucci Laser Vision Institute, 158 Wilkes-Barre Township Boulevard, Wilkes-Barre, Pennsylvania 18702, USA.
    • ,
  • L. David Waterbury, PhD

,Accepted 6 May 2008.

References 

  1. Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs. 2007;67:1291–1308
  2. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2000;11:3–6
  3. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804Available at: http://www.fasebj.org/cgi/reprint/18/7/790Accessed May 21, 2008
  4. Koay P. The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Br J Ophthalmol. 1996;80:480–485
  5. Rossetti L, Autelitano A. Cystoid macular edema following cataract surgery. Curr Opin Ophthalmol. 2000;11:65–72
  6. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother. 2006;7:99–107
  7. Solomon KD, Donnenfeld ED, Raizman M, Sandoval HP, Stern K, VanDenburgh A, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients; for the Ketorolac Reformulation Study Groups 1 and 2. J Cataract Refract Surg. 2004;30:1653–6160
  8. Sandoval HP, Fernández de Castro LE, Vroman DT, Solomon KD. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J Ocul Pharmacol Ther. 2006;22:251–257
  9. Price FW, Price MO, Zeh W, Dobbins K. Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo-controlled trial. J Refract Surg. 2002;18:140–144
  10. Donnenfeld ED, Perry HD, Wittpenn JR, Solomon R, Nattis A, Chou T. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg. 2006;32:1474–1482
  11. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin. 2004;20:2015–2019
  12. Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation; for the Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Ophthalmology. 2007;114:1653–1662
  13. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22:1133–1140
  14. Bucci FA, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (Acular LS) and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol. 2007;144:146–147

 Neither author has a financial or proprietary interest in any material or method mentioned.

 Presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, Florida, USA, May 2007.

 Supported by an unrestricted educational grant from Allergan, Inc., Irvine, California, USA.

PII: S0886-3350(08)00540-3

doi: 10.1016/j.jcrs.2008.05.023

Journal of Cataract & Refractive Surgery
Volume 34, Issue 9 , Pages 1509-1512 , September 2008

Article Tools

* Image Usage & Resolution